SCHEMBL23217654

SCHEMBL23217654

CC(C)(C)OC(=O)COc1c(C=O)cc(Br)c2occc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
KCNA3 P22001 7/20 0.33
KCNA2 P16389 2/20 0.33
KCNA5 P22460 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217709 0.83 PTGDR2 (0.46) ALDH1A1CYP2C19CYP1A2KDM4ETSHR
SCHEMBL30010993 0.83 KDM4E (0.39) ALDH1A1CYP2C19KDM4EMEN1HPGD
SCHEMBL30009732 0.83 KDM4E (0.39) ALDH1A1CYP2C19KDM4EMEN1HPGD
SCHEMBL23241694 0.83 KDM4E (0.39) ALDH1A1CYP2C19KDM4EMEN1HPGD
SCHEMBL23241702 0.83 KDM4E (0.39) ALDH1A1CYP2C19KDM4EMEN1HPGD
SCHEMBL23217206 0.78 PTPN1 (0.37) ALDH1A1CYP1A2KDM4EHPGDKCNA3
SCHEMBL23217746 0.75 NLRP3 (0.43) ALDH1A1CYP2C19CYP1A2KDM4EHPGD
SCHEMBL21468873 0.73 ALDH1A1 (0.36) ALDH1A1CYP1A2MEN1HPGDTSHR
SCHEMBL19775924 0.73 ALDH1A1 (0.36) ALDH1A1CYP1A2MEN1HPGDTSHR
SCHEMBL29481725 0.73 ALDH1A1 (0.36) ALDH1A1CYP1A2MEN1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3388/4885CYP2C19 428/4885CYP1A2 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.